Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR

John Stekelenborg (), Johan Ellenius, Simon Maskell, Tomas Bergvall, Ola Caster, Nabarun Dasgupta, Juergen Dietrich, Sara Gama, David Lewis, Victoria Newbould, Sabine Brosch, Carrie E. Pierce, Gregory Powell, Alicia Ptaszyńska-Neophytou, Antoni F. Z. Wiśniewski, Phil Tregunno, G. Niklas Norén and Munir Pirmohamed
Additional contact information
John Stekelenborg: Janssen R&D
Johan Ellenius: Uppsala Monitoring Centre
Simon Maskell: University of Liverpool
Tomas Bergvall: Uppsala Monitoring Centre
Ola Caster: Uppsala Monitoring Centre
Nabarun Dasgupta: University of North Carolina
Juergen Dietrich: Pharmacovigilance, Bayer AG
Sara Gama: Chief Medical Office and Patient Safety, Novartis Global Drug Development, Novartis Pharma Basel
David Lewis: Chief Medical Office and Patient Safety, Novartis Global Drug Development, Novartis Pharma Basel
Victoria Newbould: European Medicines Agency (EMA)
Sabine Brosch: European Medicines Agency (EMA)
Carrie E. Pierce: Booz Allen Hamilton (formerly Epidemico, Inc.)
Gregory Powell: GlaxoSmithKline, Global Clinical Safety and Pharmacovigilance, RTP
Alicia Ptaszyńska-Neophytou: Vigilance, Intelligence and Research Group, Medicines and Healthcare products Regulatory Agency (MHRA)
Antoni F. Z. Wiśniewski: AstraZeneca, Patient Safety, Office of the Chief Medical Officer, Cambridge, UK
Phil Tregunno: Vigilance, Intelligence and Research Group, Medicines and Healthcare products Regulatory Agency (MHRA)
G. Niklas Norén: Uppsala Monitoring Centre
Munir Pirmohamed: University of Liverpool

Drug Safety, 2019, vol. 42, issue 12, No 2, 1393-1407

Abstract: Abstract Over a period of 3 years, the European Union’s Innovative Medicines Initiative WEB-RADR project has explored the value of social media (i.e., information exchanged through the internet, typically via online social networks) for identifying adverse events as well as for safety signal detection. Many patients and clinicians have taken to social media to discuss their positive and negative experiences of medications, creating a source of publicly available information that has the potential to provide insights into medicinal product safety concerns. The WEB-RADR project has developed a collaborative English language workspace for visualising and analysing social media data for a number of medicinal products. Further, novel text and data mining methods for social media analysis have been developed and evaluated. From this original research, several recommendations are presented with supporting rationale and consideration of the limitations. Recommendations for further research that extend beyond the scope of the current project are also presented.

Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00858-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:12:d:10.1007_s40264-019-00858-7

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00858-7

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().